Log in to your Inderes Free account to see all free content on this page.
Genovis
28.45
SEK
-1.9 %
1,643 following
GENO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-1.9%
+8.8%
+55.29%
+15.42%
+15.18%
-1.9%
-40.23%
-20.2%
+3.92%
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Read moreMarket cap
1.86B SEK
Turnover
894.66K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
12.8.
2025
Interim report Q2'25
7.11.
2025
Interim report Q3'25
All
Press releases
ShowingAll content types
Redeye: Genovis Q1 2025 - Interesting outlook but limited near-term visibility
Communiqué from Genovis AB (publ) Annual General Meeting May 21, 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio